Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Pharmacology

Background:

• Preterm infants surviving respiratory distress syndrome (RDS) often develop chronic lung disease (CLD) due to persistent lung inflammation.
• Corticosteroids are used for CLD but their risk-benefit profile in preterm infants is unclear.

Purpose of the Study:

• To evaluate the efficacy and safety of late (>3 weeks) postnatal corticosteroid treatment for CLD in preterm infants.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) of late postnatal corticosteroid therapy for CLD in preterm infants.
• Searched major databases (Oxford Database of Perinatal Trials, Cochrane, Medline) and relevant journals.
• Analyzed data on mortality, extubation, infection, neurodevelopmental outcomes, and other clinical endpoints.

Main Results:

• Late corticosteroid therapy did not affect mortality but reduced failure to extubate and need for home oxygen.
• Short-term adverse effects included hyperglycemia and hypertension; increased severe retinopathy of prematurity was noted.
• No significant increase in infection, necrotizing enterocolitis, or gastrointestinal bleeding was observed.

Conclusions:

• Benefits of late corticosteroid therapy for CLD in preterm infants may be outweighed by potential adverse effects.
• While concerns about neurodevelopmental outcomes persist, late therapy might not significantly increase long-term risks.
• Corticosteroids should be reserved for infants difficult to wean from ventilation, with minimized dose and duration.